Optimize Cell Therapy Products: Starting Material And Manufacturing Characterization

By R. Tressler, G. Eastwood, D. Wellis, Edward X. Han, and Jing Zhou

There is a growing shift in cancer treatments that is moving away from CAR-T cell therapies and tumor infiltrating lymphocyte (TIL) that use autologous cells, to allogeneic applications instead. The shift in cancer and cell therapy treatments has already demonstrated remarkable results with numerous clinical trials ongoing or planned in the near term.

The majority of current TIL and CAR-T cell therapies use autologous cells, but there is a growing shift to allogeneic applications, as well as NK- and iPSC-based approaches, requiring access to healthy donors and starting materials to supply these demands.